
Law firm questions fairness of Nuvalent's $124/share sale to GSK amid higher analyst price targets.
Wohl & Fruchter LLP is investigating whether the proposed sale of Nuvalent, Inc. to GSK for $124 per share is fair to shareholders, noting this price is below several Wall Street analysts' targets, which range from $126 to $158 per share. The firm is...
